Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
- 1 May 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (9) , 2163-2175
Abstract
Purpose: The development of leptomeningeal melanoma metastases (LMM) is a rare and devastating complication of the late-stage disease, for which no effective treatments exist. Here, we performed a multi-omics analysis of the cerebrospinal fluid (CSF) from patients with LMM to determine how the leptomeningeal microenvironment shapes the biology and therapeutic responses of melanoma cells. Experimental Design: A total of 45 serial CSF samples were collected from 16 patients, 8 of these with confirmed LMM. Of those with LMM, 7 had poor survival (35 months). CSF samples were analyzed by mass spectrometry and incubated with melanoma cells that were subjected to RNA sequencing (RNA-seq) analysis. Functional assays were performed to validate the pathways identified. Results: Mass spectrometry analyses showed the CSF of most patients with LMM to be enriched for pathways involved in innate immunity, protease-mediated damage, and IGF-related signaling. All of these were anticorrelated in the extraordinary responder. RNA-seq analysis showed CSF to induce PI3K/AKT, integrin, B-cell activation, S-phase entry, TNFR2, TGFβ, and oxidative stress responses in the melanoma cells. ELISA assays confirmed that TGFβ expression increased in the CSF of patients progressing with LMM. CSF from poorly responding patients conferred tolerance to BRAF inhibitor therapy in apoptosis assays. Conclusions: These analyses identified proteomic/transcriptional signatures in the CSF of patients who succumbed to LMM. We further showed that the CSF from patients with LMM has the potential to modulate BRAF inhibitor responses and may contribute to drug resistance. See related commentary by Glitza Oliva and Tawbi, p. 2083Keywords
All Related Versions
Funding Information
- NIH (P50 CA168536, R21 CA198550, R21 CA216756)
- NIH (K99 CA226679)
- Department of Defense (W81XWH1810268)
- Bankhead-Coley (8BC03)
- NCI (P30-CA076292)
This publication has 57 references indexed in Scilit:
- The PRIDE database and related tools and resources in 2019: improving support for quantification dataNucleic Acids Research, 2018
- Leptomeningeal metastases: a RANO proposal for response criteriaNeuro-Oncology, 2016
- The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell ResponsesThe Journal of Immunology, 2016
- BRAF Inhibition Generates a Host–Tumor Niche that Mediates Therapeutic EscapeJournal of Investigative Dermatology, 2015
- Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowthNature, 2015
- Iterative rank-order normalization of gene expression microarray dataBMC Bioinformatics, 2013
- TGF-β signaling to T cells inhibits autoimmunity during lymphopenia-driven proliferationNature Immunology, 2012
- TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTENNature Cell Biology, 2009
- Prognostic factors and outcomes in patients with leptomeningeal melanomatosisNeuro-Oncology, 2008
- A critical function for TGF-β signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cellsNature Immunology, 2008